Automated Synthesis and Visualization of a Chemotherapy Treatment Regimen Network by Warner, Jeremy et al.
 
Automated Synthesis and Visualization of a Chemotherapy
Treatment Regimen Network
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Warner, Jeremy, Peter Yang, and Gil Alterovitz. 2013.
“Automated Synthesis and Visualization of a Chemotherapy
Treatment Regimen Network.” Studies in health technology and
informatics 192 (1): 62-66.
Accessed February 16, 2015 11:32:49 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:12406762
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAAutomated Synthesis and Visualization of a Chemotherapy
Treatment Regimen Network
Jeremy Warnera,b, Peter Yangc, and Gil Alterovitzd,e,f
aDepartment of Medicine, Division of Hematology & Oncology, Vanderbilt University, Nashville,
TN, USA
bDepartment of Biomedical Informatics, Vanderbilt University, Nashville, TN, USA
cDepartment of Medicine, Division of Hematology & Oncology, Beth Israel Deaconess Medical
Center, Boston, MA, USA
dCenter for Biomedical Informatics, Harvard Medical School, Boston, MA, USA
eChildren’s Hospital Informatics Program at Harvard-MIT Division of Health Science, Boston, MA,
USA
fDepartment of Electrical Engineering and Computer Science, Massachusetts Institute of
Technology, Cambridge, MA, USA
Abstract
Cytotoxic treatments for cancer remain highly toxic, expensive, and variably efficacious. Many
chemotherapy regimens are never directly compared in randomized clinical trials (RCTs); as a
result, the vast majority of guideline recommendations are ultimately derived from human expert
opinion. We introduce an automated network meta-analytic approach to this clinical problem, with
nodes representing regimens and edges direct comparison via RCT(s). A chemotherapy regimen
network is visualized for the primary treatment of chronic myelogenous leukemia (CML). Node
and edge color, size, and opacity are all utilized to provide additional information about the quality
and strength of the depicted evidence. Historical versions of the network are also created. With
this approach, we were able to compactly compare the results of 17 CML regimens involving
RCTs of 9700 patients, representing the accumulation of 45 years of evidence. Our results closely
parallel the recommendations issued by a professional guidelines organization, the National
Comprehensive Cancer Network (NCCN). This approach offers a novel method for interpreting
complex clinical data, with potential implications for future objective guideline development.
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tIntroduction
Conventional systematic review and meta-analysis are aggregating approaches with a goal
of making unifying conclusions based upon multiple independent studies [1]. The traditional
meta-analytic approach is generally limited by the requirement that the comparator arms and
outcome measures are the same, e.g. progression free survival (PFS) on drug A to PFS on
drug B [2]. The traditional meta-analytic approach is challenged by complex scenarios, such
as the treatment of cancer, where multiple treatment options with disparate measures of
outcome have been tested over the years. In parallel with this increase in complexity, the
issuance of clinical management guidelines has increased dramatically over the past years
and decades. Most guidelines are derived from collaborations of clinical experts and are
therefore subject to subjective interpretation of data. Furthermore, guidelines must be
constantly updated due to introductions of new evidence; one published estimate of
guideline “half-life” is only 5.5 years [3].
Several approaches have been suggested to meet the need of rigorous objective comparison
of multiple treatments used in a common context. These approaches are generally referred to
as “network meta-analyses”. Network meta-analysis evaluates multiple treatments and
determines the relationships among them, offering a powerful objective solution to this
complicated medical need, despite considerable methodological challenges [4, 5]. In this
paper, we propose a simplified approach to the construction and display of a meta-analytic
network for chemotherapy regimens, with a goal of conveying maximum information about
the quality of outcome comparisons, the comparative value of particular regimens, and the
relevance of older published regimens to contemporary practice.
Materials and Methods
Pilot Use Case
To demonstrate our proposed approach, we selected a condition with a relatively limited
number of commonly used treatments, chronic myelogenous leukemia (CML). We limited
our evaluation to published randomized clinical trials (RCTs) investigating primary (first-
line) treatments of newly-diagnosed chronic-phase CML. These were first identified through
a curated database of chemotherapy regimens at HemOnc.org (http://hemonc.org), a
hematology/oncology wiki actively maintained by physicians. The publications identified
were manually searched to identify further regimens; a PubMed query for the Medical
Subject Headings (MeSH) “Leukemia, Myelogenous, Chronic, BCR-ABL Positive” and
“Randomized Controlled Trial [Publication Type]” was also conducted. The results of this
analysis were compared to the recommendations provided by the NCCN Guidelines® [6].
Graph Attributes
A network graph was subsequently created, with v vertices corresponding to substantively
identical chemotherapy regimens and l edges connecting regimens which were directly
compared in the published RCTs. When more than one RCT compared the same regimens,
edges were duplicated. Vertices were depicted as circular nodes, and edges as solid lines.
The network layout was first automatically determined using the Kamada-Kawai force-
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tbased algorithm, with subsequent manual modification to maximize readability [7]. In order
to enhance the information value of the graph, the appearance of the nodes and edges was
enhanced in a systematic way, as follows:
Node Size and Coloration—Nodes were automatically sized proportionally to the total
number of patients who received the specified regimen. Nodes were colored using a
gradated three-color system, with red connoting an inferior treatment regimen, green a
superior treatment regimen, and yellow a treatment regimen of equivocal value. This value,
 was calculated by holding a series of m “contests” with the immediately adjacent vertices,
based on the published outcome findings. The three possible outcomes E of each contest are:
• Win (E = 1): superiority, as defined by an improved outcome with p-value ≤0.05.
• Lose (E = −1): inferiority, as defined by an inferior outcome with p-value ≤0.05.
• Tie (E = 0): either an outcome with a non-significant p-value or an equivalent
outcome as defined by formal non-inferiority, with p-value ≤0.05.
E was further multiplied by a “relative value measure” RV, representing the quality of the
measured outcome: 1.0 for a weak surrogate measure (e.g. response rate); 1.25 for a strong
surrogate measure (e.g. PFS); 1.5 for overall survival. Finally, the average of the sum of the
products of these values was multiplied by the logarithm of the total patients in all contests
involving the vertex, as shown in Equation (1):
(1)
Nodes with negative   were automatically colored in the red range, gradating towards
yellow for   about zero, and towards the green range for positive  .
Edge Width and Coloration—Edge width was automatically sized proportionate to the
number of patients being compared across the two treatment regimen vertices for the
uniquely referent RCT. If more than one RCT compared the same regimens, the width of
each duplicate edge was determined independently. Edges were also colored on a three-color
scale, without gradation, to reflect the quality of the measured outcome, which was
determined manually: red for weak surrogates (e.g. response rate); yellow for strong
surrogates (e.g. PFS); green for overall survival.
Node and Edge Aging Effects—In order to convey information about how recently a
regimen was formally evaluated, transparency was automatically assigned to older nodes
and edges, using the alpha opacity channel. Edges were assigned initial alpha of 1.0 and
decayed by 0.1/year to a minimum of 0.2, based upon the “survival analysis” by Shojania et
al [3]. Nodes were also assigned initial alpha of 1.0 and decayed in a similar fashion;
however, nodes were refreshed to an alpha of 1.0 whenever a new RCT was published
which involved the node.
Node alpha was also varied with significant perturbations of the network. Specifically, when
new evidence caused one or more extant nodes to change value (from green/superior to red/
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tinferior, or vice versa), the alpha of all nodes immediately adjacent to the changed node was
automatically refreshed to 1.0. This effect was carried over to the legend, so that nodes
determined to be aged (those with low alpha) were faintly displayed, and thus considered to
be “outdated” regimens.
Historical Representation of Meta-Analytic Network
In order to create the enhancements described above, it was necessary to temporally develop
the network, beginning with the first year of publication and proceeding to the most recent
year. As a result, visualization of changes in evidence over time was possible.
General Considerations
The analysis was undertaken using the R statistical programming language (http://www.r-
project.org/). iGraph, a freely available package for R and other applications, was used for
graph visualization (http://igraph.sourceforge.net/).
Results
We identified 24 RCTs comparing at least two treatments for newly-diagnosed CML, with
n=17 substantively identical regimens [8-31]. These are shown chronologically in Table 1.
A total of 9700 patients were enrolled across all trials.
Imatinib and busulfan were the most highly connected treatment regimens, with degree of
13 in both cases. Five treatments (29%) were singly connected to the network. Additional
graph measures are shown in Figure 1.
Figure 2 shows the enhanced graph for the year 2012.
Figure 3 shows four historical representations of the graph. Between 1992 and 1994 (top
panels), two new treatments were introduced, and the older “superior” treatment (busulfan)
transitioned to an “inferior” status. Between 2002 and 2003 (bottom panels) evidence for
imatinib was introduced, and it rose to the top of the “superior” treatment options.
An animated movie of the graph evolution from 1968 to 2012 is freely available at http://
hemonc.org/docs/CMLhistory.avi. The R code is freely available upon request.
Discussion and Conclusion
Several notable conclusions can be made by examining the modern and historical meta-
analytic network graphs. First, there is a clear inflection point in the mid-1990’s, after which
the number of regimens, clinical trials, and clinical trial participants increased rapidly
(Figure 1). Second, overall survival was substituted by surrogate outcomes from 2003
onwards, reflecting the radical improvement in prognosis of CML. While this is welcome
news, the general decrease in the quality of the outcome evidence makes interpretation of
the modern RCTs more difficult [32]. Third, several distinct “paradigm shifts” can be
discerned, based upon the phenomenon of over-turning of previously superior treatment
regimens: busulfan in 1994, hydroxyurea in 1995, and imatinib in 2010.
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tIn terms of concordance with the most recent NCCN Guidelines®, our two most superior
(and current) regimens, nilotinib and dasatinib, are recommended; the guidelines also
suggest consideration of interferon-α for patients intolerant of tyrosine kinase inhibitors
(TKI’s) [6]. Imatinib, which is ranked as an inferior regimen in Figure 2, continues to be
recommended by the NCCN. Notably, this recommendation hinges primarily on the
assertion that imatinib has shown a definitive long-term survival advantage, which is based
on historical comparisons, not RCTs (the seminal IRIS trial of imatinib vs. interferon-α/low-
dose cytarabine experienced a crossover rate of 90%, making long-term comparisons
unreliable) [33, 34]. Because our analysis only includes RCTs, this information is not
present in the visualization. This decision to include only high levels of evidence was
intentional, although future work will focus on methods of inclusion of historical and
contemporaneous comparative effectiveness data.
The treatment for chronic-phase CML has evolved through several eras, which are captured
effectively by the modern and historical graphs. In the first era, conventional chemotherapy
was the only option; several trials in the early 1990’s established the superiority of
hydroxyurea to the standard treatment since the 1940’s, busulfan. From the mid-1990’s,
improved mortality was observed with the introduction of interferon-α, ushering in the so-
called “interferon era.” The IRIS trial in 2003 led to the “imatinib era,” as shown in Figure
3, lower right panel [19]. Most recently, a series of 2nd and 3rd generation TKI’s, as well as
combinations of imatinib with other drugs, have begun to usher in the “post-imatinib era”
[35]. Of note, a curative treatment has been available through most of these eras: allogeneic
stem cell transplant [36]. As Figure 2 demonstrates, this treatment has rarely been compared
against others in a randomized fashion.
There are several important limitations to the current approach. As with any meta-analysis,
the results should be interpreted cautiously, since the study populations may differ
significantly and publication bias may be present. Additionally, we simplified the valuing of
vertices considerably by introducing a win/lose/tie schema, which does not measure the
magnitude of outcomes. Future work will explore direct incorporation of outcome
magnitudes into the model. We also did not adjust vertex value by indirect comparisons but
rather elected to let aged nodes “outdate” through a fading process, with the implications
that regimens that have not been studied for some time are unlikely to be a part of current
practice. There are clearly exceptions to this rule, such as a regimen whose utility was
proven beyond a doubt many years ago. Future work will investigate ways of resolution of
these exceptions, as well as application of inheritance rules to the graph. Multiple regimens
can contain the same drug(s) and conveyance of this information will require further
refinement. Finally, this visualization includes neither comparative effectiveness data nor
the other two components of quality measurement: toxicity and cost. In order to make fully
informed decisions about optimal treatment strategy, this information is usually taken under
consideration; its inclusion in the automated network analysis will also be the focus of future
work.
In conclusion, we have demonstrated a new approach to the analysis and visualization of
complex clinical data, which does not rely on subjective human interpretation. In the
example of primary treatment of CML, the constructed hierarchy closely parallels that
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tdeveloped by human expert consensus. Our method is generalizable and should therefore
work with more complicated disease phenotypes and contexts, such as the adjuvant
treatment of breast cancer. Once more broadly validated, this automated method has the
potential to augment or replace the current approach to guideline development.
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the right panel, total number of patients is normalized to 100 (year 2012)
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Table 1
Summary of RCTs
Author (year) Regimen 1 Regimen 2
Witts et al. (1968) Busulfan Radiation
Canellos et al. (1975) Busulfan DBM
Silver et al. (1987) Busulfan DBM
Hehlmann et al. (1993) Busulfan Hydrea
Tura et al. (1994) Busulfan Hydrea IFNA
Hehlmann et al. (1994) Busulfan Hydrea IFNA
Allan et al. (1995) Busulfan Hydrea
Busulfan/IFNA Hydrea/IFNA
Ohnishi et al. (1995) Busulfan IFNA
Guilhot et al. (1997) IFNA IFNA/LoDAC
Baccarani et al. (2002) IFNA IFNA/LoDAC
Kuhr et al. (2003) Hydrea/IFNA IFNA/LoDAC
O’Brien et al. (2003) IFNA/LoDAC Imatinib
Ohnishi et al. (2004) IFNA MRD allo-SCT
Olsson et al. (2004) Busulfan Hydrea
Deenik et al. (2007) IFNA/HiDAC IFNA/LoDAC
Baccarani et al. (2009) Imatinib Imatinib-HD
Cortes et al. (2010) Imatinib Imatinib-HD
Kantarjian et al. (2010) Dasatinib Imatinib
Preudhomme et al. (2010) Imatinib Imatinib-HD
Imatinib/IFNA Imatinib/LoDAC
Saglio et al. (2010) Imatinib Nilotinib
Hehlmann et al. (2011) Imatinib Imatinib-
HD
Imatinib/
IFNA
Simonsson et al. (2011) IFNA/Imatinib Imatinib
Cortes et al. (2012) Bosutinib Imatinib
Radich et al. (2012) Dasatinib Imatinib
DBM: dibromomannitol; Hydrea: hydroxyurea; IFNA: interferon-α; Lo/HiDAC: low-/high-dose cytarabine; MRD allo-SCT: matched related
donor allogeneic stem cell transplant; HD: high dose
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